{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:05:44Z","timestamp":1787875544080,"version":"build-2784847793"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011485","name":"University of North Carolina at Chapel Hill Translational and Clinical Sciences Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011485","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R21 NS119867-01A1"],"award-info":[{"award-number":["R21 NS119867-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Global Epidemiology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.gloepi.2024.100145","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T22:47:22Z","timestamp":1714690042000},"page":"100145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Evaluating algorithms for identifying incident Guillain-Barr\u00e9 Syndrome in Medicare fee-for-service claims"],"prefix":"10.1016","volume":"7","author":[{"given":"Samantha R.","family":"Eiffert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Traub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.gloepi.2024.100145_bb0005","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/WCO.0000000000000602","article-title":"Advances in management of Guillain-Barr\u00e9 syndrome","volume":"31","author":"Doets","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.gloepi.2024.100145_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jneuroim.2016.02.003","article-title":"A retrospective analysis of possible triggers of Guillain-Barre syndrome","volume":"293","author":"Yang","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"3","key":"10.1016\/j.gloepi.2024.100145_bb0015","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1212\/CPJ.0000000000000451","article-title":"Clinical factors associated with Guillain-Barr\u00e9 syndrome following surgery","volume":"8","author":"Hocker","year":"2018","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"10.1016\/j.gloepi.2024.100145_bb0020","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/ene.12565","article-title":"The incidence and triggers of adult-onset Guillain-Barr\u00e9 syndrome in southwestern Finland 2004-2013","volume":"22","author":"Sipil\u00e4","year":"2015","journal-title":"Eur J Neurol"},{"issue":"16","key":"10.1016\/j.gloepi.2024.100145_bb0025","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1605564","article-title":"Guillain\u2013Barr\u00e9 syndrome associated with Zika virus infection in Colombia","volume":"375","author":"Parra","year":"2016","journal-title":"N Engl J Med"},{"issue":"10027","key":"10.1016\/j.gloepi.2024.100145_bb0030","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(16)00562-6","article-title":"Guillain-Barr\u00e9 syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study","volume":"387","author":"Cao-Lormeau","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.gloepi.2024.100145_bb0035","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ajem.2020.07.074","article-title":"Guillain-Barr\u00e9 syndrome in a patient previously diagnosed with COVID-19","volume":"45","author":"Defabio","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"1","key":"10.1016\/j.gloepi.2024.100145_bb0040","doi-asserted-by":"crossref","DOI":"10.1186\/s42466-020-00066-0","article-title":"Guillain-Barr\u00e9 syndrome and SARS-CoV-2","volume":"2","author":"Lampe","year":"2020","journal-title":"Neurol Res Pract"},{"issue":"5","key":"10.1016\/j.gloepi.2024.100145_bb0045","first-page":"797","article-title":"Severe rapidly progressive Guillain-Barr\u00e9 syndrome in the setting of acute COVID-19 disease","volume":"26","author":"Abrams","year":"2020","journal-title":"J Neuro-Oncol"},{"issue":"6","key":"10.1016\/j.gloepi.2024.100145_bb0050","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s10072-020-04449-8","article-title":"Early Guillain-Barr\u00e9 syndrome in coronavirus disease 2019 (COVID-19): a case report from an Italian COVID-hospital","volume":"41","author":"Ottaviani","year":"2020","journal-title":"Neurol Sci"},{"issue":"2","key":"10.1016\/j.gloepi.2024.100145_bb0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000324710","article-title":"Population incidence of Guillain-Barr\u00e9 syndrome: A systematic review and meta-analysis","volume":"36","author":"Sejvar","year":"2011","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.gloepi.2024.100145_bb0060","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/CLEP.S104448","article-title":"Helping everyone do better: a call for validation studies of routinely recorded health data","volume":"8","author":"Ehrenstein","year":"2016","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.gloepi.2024.100145_bb0065","series-title":"Validation of algorithms in studies based on routinely collected health data: General principles","author":"Ehrenstein","year":"2021"},{"issue":"16","key":"10.1016\/j.gloepi.2024.100145_bb0070","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.vaccine.2013.02.009","article-title":"Algorithms for identification of Guillain\u2013Barr\u00e9 Syndrome among adolescents in claims databases","volume":"31","author":"Funch","year":"2013","journal-title":"Vaccine"},{"issue":"43","key":"10.1016\/j.gloepi.2024.100145_bb0075","doi-asserted-by":"crossref","first-page":"6543","DOI":"10.1016\/j.vaccine.2019.08.045","article-title":"Surveillance for Guillain-Barr\u00e9 syndrome after 2015\u20132016 and 2016\u20132017 influenza vaccination of Medicare beneficiaries","volume":"37","author":"Arya","year":"2019","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.gloepi.2024.100145_bb0080","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/aje\/kws195","article-title":"Risk of confirmed Guillain-Barr\u00e9 syndrome following receipt of monovalent inactivated influenza a (H1N1) and seasonal influenza vaccines in the vaccine safety datalink project, 2009\u20132010","volume":"175","author":"Greene","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.gloepi.2024.100145_bb0085","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/aje\/kwt051","article-title":"Chart-confirmed Guillain-Barr\u00e9 syndrome after 2009 H1N1 influenza vaccination among the Medicare population, 2009\u20132010","volume":"178","author":"Polakowski","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.gloepi.2024.100145_bb0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.amepre.2010.05.022","article-title":"Evaluation of Guillain-Barr\u00e9 syndrome among recipients of influenza vaccine in 2000 and 2001","volume":"39","author":"Burwen","year":"2010","journal-title":"Am J Prev Med"},{"issue":"6","key":"10.1016\/j.gloepi.2024.100145_bb0095","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/cid\/cir960","article-title":"Recurrent guillain-barr\u00e9 syndrome following vaccination","volume":"54","author":"Baxter","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.gloepi.2024.100145_bb0100","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10072-019-04156-z","article-title":"Guillain-Barr\u00e9 syndrome and antecedent cytomegalovirus infection, United States 2009\u20132015","volume":"41","author":"Leung","year":"2020","journal-title":"Neurol Sci"},{"issue":"5","key":"10.1016\/j.gloepi.2024.100145_bb0105","article-title":"Significance of Brighton criteria in the early diagnosis and Management of Guillain-Barr\u00e9 Syndrome","volume":"12","author":"Ghazanfar","year":"2020","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.gloepi.2024.100145_bb0110","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1553-2712.1996.tb03538.x","article-title":"Statistical methodology: I. Incorporating the prevalence of disease into the sample size calculation for sensitivity and specificity","volume":"3","author":"Buderer","year":"1996","journal-title":"Acad Emerg Med Off J Soc Acad Emerg Med"},{"issue":"6","key":"10.1016\/j.gloepi.2024.100145_bb0115","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/pds.1924","article-title":"Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population","volume":"19","author":"Wahl","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.gloepi.2024.100145_bb0120","first-page":"27","article-title":"More accurate racial and ethnic codes for medicare administrative data","volume":"29","author":"Eicheldinger","year":"2008","journal-title":"Health Care Financ Rev"},{"issue":"4","key":"10.1016\/j.gloepi.2024.100145_bb0125","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/00001648-199607000-00011","article-title":"Correcting for exposure misclassification using an alloyed gold standard","volume":"7","author":"Brenner","year":"1996","journal-title":"Epidemiology"},{"issue":"2","key":"10.1016\/j.gloepi.2024.100145_bb0130","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000494923","article-title":"Analysis of Nationwide data to determine the incidence and diagnosed prevalence of autosomal dominant polycystic kidney disease in the USA: 2013\u20132015","volume":"5","author":"Willey","year":"2019","journal-title":"Kidney Dis"},{"key":"10.1016\/j.gloepi.2024.100145_bb0135","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.pediatrneurol.2020.01.017","article-title":"Pediatric Guillain-Barr\u00e9 syndrome in a 30-year Nationwide cohort","volume":"107","author":"Levison","year":"2020","journal-title":"Pediatr Neurol"}],"container-title":["Global Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590113324000117?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590113324000117?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:04:41Z","timestamp":1778907881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590113324000117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":27,"alternative-id":["S2590113324000117"],"URL":"https:\/\/doi.org\/10.1016\/j.gloepi.2024.100145","relation":{},"ISSN":["2590-1133"],"issn-type":[{"value":"2590-1133","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating algorithms for identifying incident Guillain-Barr\u00e9 Syndrome in Medicare fee-for-service claims","name":"articletitle","label":"Article Title"},{"value":"Global Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gloepi.2024.100145","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100145"}}